Abstract
Cannabinoids are compounds isolated from cannabis and are also widely present in both nervous and immune systems of animals. In recent years, with in-depth research on cannabinoids, their clinical medicinal value has been evaluated, and many exciting achievements have been con-tinuously accumulating, especially in the field of neurodegenerative disease. Alzheimer's disease is the most common type of neurodegenerative disease that causes dementia and has become a global health problem that seriously impacts human health today. In this review, we discuss the therapeutic potential of cannabinoids for the treatment of Alzheimer’s disease. How cannabinoids act on differ-ent endocannabinoid receptor subtypes to regulate Alzheimer’s disease and the roles of the endo-cannabinoid system in Alzheimer’s disease are outlined, and the underlying mechanisms are dis-cussed. Finally, we summarize the most relevant opportunities of cannabinoid pharmacology related to Alzheimer’s disease and discuss the potential usefulness of cannabinoids in the clinical treatment of Alzheimer’s disease.
Original language | English (US) |
---|---|
Pages (from-to) | 715-726 |
Number of pages | 12 |
Journal | Current Neuropharmacology |
Volume | 21 |
Issue number | 3 |
DOIs | |
State | Published - 2023 |
Externally published | Yes |
Keywords
- Alzheimer's disease
- CB1 receptor
- CB2 receptor
- Cannabinoids
- endocannabinoid
- neurodegenerative diseases
ASJC Scopus subject areas
- Pharmacology
- Neurology
- Clinical Neurology
- Psychiatry and Mental health
- Pharmacology (medical)